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Editorial
Treatment of bacterial infections
This  issue  of  the  journal  has  again  a  theme  -  that  of 
diagnosis and treatment of infection in its various guises. It 
is not that long since a simple cut or abrasion could result 
in  overwhelming  septicaemia  and  death  due  to  lack  of 
suitable treatment by antibiotics – which today we all take 
for granted. Hedley-Whyte and Milamed nicely illustrate the 
progression of treatment of pneumonia over the years with 
the development of sulpha drugs and later penicillin. Several 
of the key players involved in pioneering the treatments were 
linked to Belfast medicine in various ways1.  Pneumonitis 
is not always bacterial and may rarely be caused by viral 
infections such as Epstein Barr virus2 or by tuberculosis (TB). 
Tuberculosis is again on the increase most recently with the 
arrival of immigrant workers, so the picture of lung disease 
changes steadily from decade to decade. In the 2008 Annual 
oration, Dr Rory Corbett discusses the downside of some 
dermatology treatments with reactivation of TB and other 
skin manifestations of systemic disease3 Two more recent 
scourges, however, are the rising incidence of drug induced 
pneumonia, and of antimicrobial resistance to drugs (fig 1)4. 
Cocaine users are increasingly presenting at our emergency 
departments with characteristic lung findings, and the use 
of cocaine and other drugs and recent trends show a steady 
rise  in  use5.  Similarly  with  resistance,  Moore  and  others 
describe  increasing  antibiotic  resistance  to  campylobacter 
gastroenteritis in Northern Ireland and suggest a need for 
General  Practitioners  and  other  medical  professionals  to 
be aware of the correct treatments6. Perhaps this is one area 
that will increasingly feature in the reorganised quality and 
outcomes framework (QOF) as topics are selected in the four 
countries of the United Kingdom by a new mechanism7. 
For one scourge – MRSA – hope is in sight as researchers 
at  Queens  University  Belfast  have  identified  that  ionic 
liquids possess potent broad spectrum antibiofilm activity 
so our hospitals may be much cleaner in the near future if a 
commercial application of such liquids can be developed8.
Patrick J Morrison, Honorary Editor.
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Fig 1. Resistance (left plate) and sensitivity (right plate) to MRSA. 
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